| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/28/2003 | CA2273327C Stabilized ascorbyl compositions |
| 01/28/2003 | CA2222698C Use of bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss |
| 01/28/2003 | CA2108369C Method and composition for ameliorating the adverse effects of aging |
| 01/28/2003 | CA2094491C Alteration of rate and character of hair growth |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006495A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006072A1 A method of treatment and/or prophylaxis of ulcers |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006005A1 Composition comprising sulfacetamide and a sunscreen for the treatment of rosacea |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003006001A1 ß-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 01/23/2003 | WO2003005988A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 01/23/2003 | WO2003005980A2 Cosmetic and dermatological preparations containing carnitine |
| 01/23/2003 | WO2003005978A1 Remedy against skin diseases |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005966A2 Topical medicine and process and apparatus for making same |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005811A1 Il-18 transgenic animal |
| 01/23/2003 | WO2002080842A3 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055017A3 Method of treating autoimmune diseases |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002019981A3 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002002771A3 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/23/2003 | US20030018222 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018084 Beta-adrenergic blockade reversal of catabolism after severe burn |
| 01/23/2003 | US20030018074 Antiinflammatory agents; skin disorders; topical applying |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018063 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018058 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017970 Wound healing compositions |
| 01/23/2003 | US20030017969 Methods and pharmaceutical compositions for healing wounds |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017512 Angiostatin receptor |
| 01/23/2003 | US20030017181 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |
| 01/23/2003 | US20030017177 Topical application of compositions containing an alkanolamine such as ethylaminoethanol, methylaminoethanol |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453340A1 .beta.-adrenergic blockade reversal of catabolism after severe burn |
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | CA2453161A1 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | CA2453153A1 A method of treatment and/or prophylaxis of ulcers |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277474A1 Combination of arnica, ruscus and menthol |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276760A2 Polyamide nucleic acid derivatives, agents and methods for producing them |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276740A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276732A1 Amides of r-2-(aminoaryl)-propionic acids for use in theprevention of leucocyte activation" |
| 01/22/2003 | EP1276726A2 Substituted phenyl farnesyltransferase inhibitors |
| 01/22/2003 | EP1276725A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276471A2 Membrane delivery system |
| 01/22/2003 | EP1276460A1 Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa |
| 01/22/2003 | EP1276459A1 Cosmetic or dermatological cream composition, the preparation and the use thereof |